卵巢透明亮細胞癌，一種難治療且晚期存活率偏低的卵巢癌，其致癌基因BMAL2 recently discovered by the Institute's genetic center research team has opened up a new avenue for treatment. BMAL2, a biological clock gene, plays a crucial role in the growth of cancer cells by maintaining their DNA repair capabilities and resistance to apoptosis. The discovery of a small molecule drug, GW833972A, which can degrade BMAL2 protein and weaken DNA repair ability, has shown promising results in tumor suppression and cancer cell survival reduction in both in vitro and in vivo experiments. Furthermore, this drug enhances the therapeutic effect of PARP inhibitors, particularly in cancer cells with high BMAL2 expression. This research not only sheds light on the role of BMAL2 in the growth of this specific type of cancer but also presents a potential treatment target for future clinical strategies. The findings, published in EMBO Molecular Medicine, highlight the importance of BMAL2 in cancer biology and offer a novel approach to combating this challenging disease.
